I am a physician with special expertise in the management of infections in patients with weakened immune systems. Patients undergoing chemotherapy or bone marrow transplantation are more vulnerable to infection than healthy individuals. These patients may develop infections that present with unusual severity. I monitor regularly all infections that develop in Memorial Hospital’s Bone Marrow Transplant Unit to detect unusual trends and to assist in improving the outcome of infections. Even among our highly immunocompromised patients, there is significant variability in their susceptibility to infection.
My primary research interests focus on genetic differences of innate immune responses, which may help explain why some immunocompromised patients are more susceptible to infection than others. The long-term goal of our studies is to provide strategies to identify subsets of immunocompromised patients who are most vulnerable to infection.
- Clinical Expertise: Infections in Transplant Patients and Other Immunocompromised Patients
- Languages Spoken: English
- Education: MD, National University of Athens School of Medicine(Greece)
- Residencies: Tufts University School of Medicine
- Fellowships: Mount Sinai Medical Center (New York); Brown University School of Medicine
- Board Certifications: Internal Medicine; Infectious Diseases
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Genovefa Papanicolaou
- A Phase II Study Assessing the Effectiveness of a New Vaccine for Preventing Shingles in Patients Who Had an Autologous Stem Cell Transplant
- A Phase III Study of CMX001 versus Placebo to Prevent Cytomegalovirus (CMV) Infection in Stem Cell Transplant Recipients Already Exposed to CMV
- A Study of Posaconazole Versus Micafungin to Protect Against Invasive Fungal Infections in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome